Larinject Injection contains Ferric Carboxymaltose 50 mg/ml, an intravenous iron formulation indicated for the treatment of iron deficiency anemia when oral iron preparations are ineffective or cannot be used. Ferric Carboxymaltose is a stable complex that allows controlled release of iron, facilitating rapid replenishment of iron stores and correction of hemoglobin levels. It is particularly useful in patients with chronic kidney disease, inflammatory bowel disease, postpartum anemia, or those undergoing chemotherapy. Larinject provides a well-tolerated alternative to traditional iron therapies, minimizing gastrointestinal side effects commonly associated with oral iron. The dosage and administration should be individualized based on the patient’s iron deficit, with careful monitoring of iron parameters to avoid iron overload. Adverse reactions may include hypersensitivity reactions, hypotension, nausea, dizziness, and injection site reactions; therefore, administration should be performed under medical supervision with emergency facilities available. Larinject is contraindicated in patients with known hypersensitivity to Ferric Carboxymaltose or any of its excipients, and in cases of iron overload disorders such as hemochromatosis. Proper patient evaluation and adherence to recommended dosing guidelines are essential to ensure safety and efficacy in the management of iron deficiency anemia.